SCHEMBL30167652

SCHEMBL30167652

FC(F)COc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN4A P35499 2/20 0.52
CYP1A2 P05177 1/20 0.47
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
MAPK1 P28482 1/20 0.44
SIGMAR1 Q99720 4/20 0.42
CACNA1G O43497 2/20 0.42
KCNH2 Q12809 2/20 0.42
MAOB P27338 3/20 0.42
APP P05067 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17897227 0.78 KMT2A (0.47) MAPK1NPC1RAB9AALDH1A1
SCHEMBL1588646 0.77 APP (0.50) APP
SCHEMBL15858992 0.77 USP2 (0.49) CYP1A2KCNH2DRD2DRD4DRD3
SCHEMBL241012 0.77 TDP1 (0.52) MAPK1MAOBAPPNPC1RAB9A
SCHEMBL2312172 0.77 SCN4A (0.52) SCN4ACYP1A2PPARGPPARAMAPK1
SCHEMBL24272288 0.77 CYP1A2 (0.56) SCN4ACYP1A2PPARGPPARAMAPK1
SCHEMBL7764964 0.77 MAPT (0.46) MAPK1APPDRD2DRD4DRD3
SCHEMBL14954600 0.76 LMNA (0.56) SCN4AALDH1A1
SCHEMBL9229780 0.76 LMNA (0.56) SCN4AALDH1A1
SCHEMBL1496603 0.75 CYP1A2 (0.58) CYP1A2MAPK1CACNA1GKCNH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT SCN4A 1694/4885CYP1A2 1048/4885PPARG 738/4885
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 SCN4A 1739/4885CYP1A2 1024/4885PPARG 832/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 SCN4A 1551/4885CYP1A2 2270/4885PPARG 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.